[422 Pages Report] The global vascular endothelial growth factor inhibitors market is expected to enjoy a valuation of US$ 22.7 Billion by the end of the year 2022, and further expand at a CAGR of 4.0% to reach a valuation of ~US$ 33.5 Billion by the year 2032. According to a recent study by Future Market Insights, biologics are leading the market as drugs, with a share of about 72.1% in the year 2021, within the global market.
Market Outlook:
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 21.2 Billion |
|
Market Value 2022 |
US$ 22.7 Billion |
|
Market Value 2032 |
US$ 33.5 Billion |
|
CAGR 2022 to 2032 |
4.0% |
|
Market Share of Top 5 Countries |
71.5% |
|
Key Market Players |
Pfizer Inc., Novartis AG, Sanofi SA, Bayer Healthcare LLC, F. Hoffmann-La Roche Ltd, Amgen Inc., Eli Lilly and Company, Eisai Co., Ltd., Sino Pharma, Amneal Pharmaceuticals Inc., Exelixis, Inc., HUTCHMED, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Company Limited |
VEGF inhibitors have been and continue to be the subject of research for a range of medical applications. VEGF inhibitor research is rapidly developing, both at research institutes and in numerous therapeutic clinical applications. Manufacturers are investing heavily in research to create novel VEGF inhibitor drugs for a variety of therapeutic applications. VEGF inhibitor clinical studies focus on therapeutic applications such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular diseases.
The market value for vascular endothelial growth factor inhibitors was approximately 12.0% of the overall ~US$ 177.4 Billion of the global oncology therapeutic medicines market in 2021.
The sales of vascular endothelial growth factor inhibitors expanded at a CAGR of 8.5% from 2012 to 2021.
Following the development of vascular endothelial growth factor (VEGF) inhibitor intravitreal injection techniques, treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders have significantly increased. However, because intravitreal treatment necessitates repeat injections every month or two to be effective, recent research has focused on extended drug delivery mechanisms to prolong treatment intervals over the long term.
Preclinical and clinical research is currently being performed on drug dosage escalation and molecular weight, intravitreal implants and nanoparticles, hydrogels, combination systems, and port delivery systems. Additionally, less invasive methods including topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral delivery routes have been investigated to reduce the treatment burden.
Recently, advancements such as dendrimer-encapsulated drug molecules, allowing for a controlled release in the intraocular space, have entered preclinical trials. Using a laser-induced choroidal neovascularization (CNV) model, Marano et al. designed and examined a dendrimer-conjugated VEGF inhibitor drug. According to studies, penetration into the retinal layer and reduction of CNV were achieved for 6 months.
In addition, liposomes can encapsulate various types of molecules despite their physiochemical properties, and liposome intravitreal injections for retinal disorders have also been investigated.
According to a study conducted by Abrishami et al., Bevacizumab encapsulated in nanoliposomes retained VEGF inhibitor drug concentration in the intraocular space greater than the amount of free bevacizumab.
Ocular drug delivery to the retina has been thoroughly studied over the past decade. In addition, the commercial market has significantly grown since the development of VEGF inhibitor drugs and is expected to boost the VEGF inhibitors market.
Thus, owing to the aforementioned factors, the global vascular endothelial growth factor inhibitors market is expected to grow at a CAGR of 4.0% during the forecast period from 2022 to 2032.
Biobetters can be expensive to research and develop, but given the right target and an extremely effective original biologic, there is a very high likelihood that they will eventually reach the production stage.
Another benefit is that a bio better's research and development timeline is significantly less than that of an innovative molecule. Biobetters are regarded as investigational new drugs (IND), which means that a pharmaceutical company can request FDA approval to begin human clinical trials and authorize the shipment of the experimental drug across state boundaries before the approval of the specific drug's marketing application. As a result, they can generate higher and faster financial returns for businesses than biosimilars, as there's no need to wait for the patents and market exclusivity to expire, as is the case with biosimilars.
The VEGF inhibitor market has the potential to grow exponentially, as drug manufacturers are showing a keen interest in manufacturing bio betters of VEGF inhibitor drugs. For instance,
Genentech is currently working on a ranibizumab port-based delivery system. The objective is to enhance drug delivery while boosting efficacy and minimizing total treatment costs.
Ildong Pharmaceuticals is also developing a bio better based on Ranibizumab to increase efficacy and lower drug resistance for age-related macular degeneration patients.
With the introduction of bio betters and the clinical evaluation for the same for several disease indications, the manufacturers within the market are presented with lucrative opportunities for expansion.
Vascular endothelial growth factor inhibitors are the main treatment for neovascular age-related macular degeneration (AMD). There are now four biologics approved for the treatment of neovascular AMD: aflibercept, ranibizumab, brolucizumab-dbll, and one biologic that is frequently used off-label (bevacizumab).
Between 2015 and 2019, Medicare spending on these medications in the USA continuously exceeded $4 billion a year. This was largely due to high costs and various off-label uses of bevacizumab, which is significantly less expensive than the other biologics used to treat neovascular AMD.
Despite significant clinical advantages, VEGF inhibitor drugs are expensive. VEGF inhibitors were among the most expensive drugs for Medicare, with reported fee-for-service spending of $5.21 billion in 2019. However, whilst the average sales price (ASP) for aflibercept and ranibizumab in 2019 was $1877 and $1717 per dose, respectively, the off-label use of bevacizumab for retinal disorders is far less expensive (around $70/dose).
The high cost of drugs and biologics for VEGF inhibitor treatments will pose itself to be a major restraint towards the market growth, over the forecasted years.
The US dominates the North American region with a total market share of about 95.3% in 2021 and is expected to continue to experience the same growth throughout the forecast period. Growing FDA approvals for novel drugs and biologics are propelling the sales of the vascular endothelial growth factor inhibitors market within the country.
China holds approximately 47.9% share of the East Asia market in 2021. For the treatment of retinal diseases, China has recently approved the use of the concept, by Chengdu Kanghong Pharmaceutical Group, and this key development is set to aid with the burden of ocular and retinal diseases in the country, thus propelling the overall market value during the forecast period.
Germany is set to exhibit growth at a CAGR of nearly 2.9% in the European vascular endothelial growth factor inhibitors market during the forecast period. With the presence of established key players such as Novartis, the market for vascular endothelial growth factor inhibitors gains a significant market share, owing to the authorized marketing of therapeutics and biologics after significant overlooking by the regulatory bodies.
Biologics are expected to present high growth at a CAGR of 3.6% by the end of the forecast period. With growing activities, such as outsourcing for research and manufacture of biopharmaceuticals, globally, the biologics segment holds a large market share of around 72.1% within the vascular endothelial growth factor inhibitors market.
VEGF A inhibitors hold a revenue share of 49.2% in 2021. Since the growth factor, VEGF A is produced by macrophages, tumor cells, platelets, and keratinocytes, the VEGF A inhibitors segment holds a greater focus for research and development. This is owed to the increasing demand for novel therapeutic modalities to cater to the growing disease burden, worldwide.
The oncology segment holds a market share of around 95.4% in the global market, in 2021. Companies in the biopharmaceutical industry are creating a pipeline of cutting-edge therapeutic options in response to the rising incidence of cancer. Clinical practices, including those used in oncology clinical trials, are constantly evolving, as are the needs for supportive services, thus promoting the market share growth for this segment.
Hospitals hold the highest market share of around 49.5% during the year 2021. Being the prime unit for medical care and health services, hospitals offer therapeutic and treatment modalities for several indications utilizing VEGF inhibitors, thus promoting this segment as a prime distribution channel within the vascular endothelial growth factor inhibitors market.
Some trends seen among the major market participants include sustainable development strategies, acquisitions, and collaborations in research activities, as well as manufacturing capabilities. Following thorough clinical evaluations, key players are also concentrating on product invention and launch operations.
Instances of key developmental strategies by the industry players in the vascular endothelial growth factor inhibitors market are given below:
Similarly, recent developments related to companies manufacturing vascular endothelial growth factor inhibitors have been tracked by the team at Future Market Insights, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2012 to 2021 |
|
Historical Data Available for |
2022 to 2032 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa (MEA) |
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
|
Key Market Segments Covered |
Drugs, Types, Disease Indication, Distribution Channel, and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
1. Executive Summary | Vascular Endothelial Growth Factor Inhibitor Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Influencing the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Regulatory Landscape
4.2. Pipeline Assessment
4.3. Product Adoption and Usage Analysis
4.4. Key Marketing & Promotional Strategies Adopted by Companies
4.5. PESTLE Analysis
4.6. Porter’s Analysis
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Oncology Therapeutic Medicines Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in Research and Development Funding and Grants
5.2.2. Rising Research Activities for Rare Disease Indications
5.2.3. High Demand for Biologics
5.2.4. Surge in Research Collaborations for the Development of Drugs
5.2.5. High Prevalence of Cancer
5.2.6. New Product Launch
5.2.7. Regulatory Approvals
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug
6.1.2. Revenue By Types
6.1.3. Revenue By Disease Indication
6.1.4. Revenue By Distribution Channel
6.1.5. Revenue By Country
6.2. 2021 Market Scenario
7. Global Vascular Endothelial Growth Factor Inhibitors Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Drug
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis, By Drug, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug, 2022 to 2032
8.3.1. Small Molecules
8.3.1.1. Pazopanib
8.3.1.2. Sunitinib
8.3.1.3. Regorafenib
8.3.1.4. Cabozantinib
8.3.1.5. Lenvatinib
8.3.1.6. Ponatinib
8.3.1.7. Axitinib
8.3.1.8. Tivozanib
8.3.1.9. Vandetanib
8.3.1.10. Sorafenib
8.3.1.11. Anlotinib
8.3.1.12. Apatinib
8.3.1.13. Fruquintinib
8.3.1.14. Surufatinib
8.3.2. Biologics
8.3.2.1. Bevacizumab
8.3.2.2. Ziv-Aflibercept
8.3.2.3. Ramucirumab
8.4. Market Attractiveness Analysis By Drug
9. Global Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Types
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Types, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Types, 2022 to 2032
9.3.1. VEGF A Inhibitors
9.3.2. VEGF B Inhibitors
9.3.3. VEGF C Inhibitors
9.3.4. Placenta Growth Factor Inhibitors
9.4. Market Attractiveness Analysis By Types
10. Global Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Disease Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Disease Indication, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Indication, 2022 to 2032
10.3.1. Oncology
10.3.1.1. Cervical Cancer
10.3.1.2. Non-Small Cell Lung Cancer
10.3.1.3. Renal Cell Carcinoma
10.3.1.4. Soft Tissue Sarcoma
10.3.1.5. Colorectal Cancer
10.3.1.6. Liver Cancer
10.3.1.7. Others
10.3.2. Hematology Disorders
10.3.3. Ophthalmology Disorders
10.3.3.1. Wet Age-Related Macular Degeneration (AMD)
10.3.3.2. Diabetic Retinopathy
10.3.3.3. Others
11. Global Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Mail Order Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
13. North America Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
13.3.1. By Country
13.3.1.1. The US
13.3.1.2. Canada
13.3.2. By Drug
13.3.3. By Types
13.3.4. By Disease Indication
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Types
13.4.4. By Disease Indication
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Country-Level Analysis & Forecast
13.7.1. The US Vascular Endothelial Growth Factor Inhibitors Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Drug
13.7.1.2.2. By Types
13.7.1.2.3. By Disease Indication
13.7.1.2.4. By Distribution Channel
13.7.2. Canada Vascular Endothelial Growth Factor Inhibitors Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Drug
13.7.2.2.2. By Types
13.7.2.2.3. By Disease Indication
13.7.2.2.4. By Distribution Channel
14. Latin America Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug
14.3.3. By Types
14.3.4. By Disease Indication
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Types
14.4.4. By Disease Indication
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Vascular Endothelial Growth Factor Inhibitors Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug
14.8.1.2.2. By Types
14.8.1.2.3. By Disease Indication
14.8.1.2.4. By Distribution Channel
14.8.2. Brazil Vascular Endothelial Growth Factor Inhibitors Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug
14.8.2.2.2. By Types
14.8.2.2.3. By Disease Indication
14.8.2.2.4. By Distribution Channel
14.8.3. Argentina Vascular Endothelial Growth Factor Inhibitors Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug
14.8.3.2.2. By Types
14.8.3.2.3. By Disease Indication
14.8.3.2.4. By Distribution Channel
15. Europe Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. The UK
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Russia
15.3.1.9. Rest of Europe
15.3.2. By Drug
15.3.3. By Types
15.3.4. By Disease Indication
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Types
15.4.4. By Disease Indication
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug
15.8.1.2.2. By Types
15.8.1.2.3. By Disease Indication
15.8.1.2.4. By Distribution Channel
15.8.2. Italy Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug
15.8.2.2.2. By Types
15.8.2.2.3. By Disease Indication
15.8.2.2.4. By Distribution Channel
15.8.3. France Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug
15.8.3.2.2. By Types
15.8.3.2.3. By Disease Indication
15.8.3.2.4. By Distribution Channel
15.8.4. U.K. Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug
15.8.4.2.2. By Types
15.8.4.2.3. By Disease Indication
15.8.4.2.4. By Distribution Channel
15.8.5. Spain Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug
15.8.5.2.2. By Types
15.8.5.2.3. By Disease Indication
15.8.5.2.4. By Distribution Channel
15.8.6. BENELUX Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug
15.8.6.2.2. By Types
15.8.6.2.3. By Disease Indication
15.8.6.2.4. By Distribution Channel
15.8.7. Nordic Countries Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug
15.8.7.2.2. By Types
15.8.7.2.3. By Disease Indication
15.8.7.2.4. By Distribution Channel
15.8.8. Russia Vascular Endothelial Growth Factor Inhibitors Market Analysis
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast by Market Taxonomy
15.8.8.2.1. By Drug
15.8.8.2.2. By Types
15.8.8.2.3. By Disease Indication
15.8.8.2.4. By Distribution Channel
16. East Asia Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Drug
16.3.3. By Types
16.3.4. By Disease Indication
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Types
16.4.4. By Disease Indication
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country-Level Analysis & Forecast
16.8.1. China Vascular Endothelial Growth Factor Inhibitors Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug
16.8.1.2.2. By Types
16.8.1.2.3. By Disease Indication
16.8.1.2.4. By Distribution Channel
16.8.2. Japan Vascular Endothelial Growth Factor Inhibitors Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug
16.8.2.2.2. By Types
16.8.2.2.3. By Disease Indication
16.8.2.2.4. By Distribution Channel
16.8.3. South Korea Vascular Endothelial Growth Factor Inhibitors Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug
16.8.3.2.2. By Types
16.8.3.2.3. By Disease Indication
16.8.3.2.4. By Distribution Channel
17. South Asia Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Drug
17.3.3. By Types
17.3.4. By Disease Indication
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Types
17.4.4. By Disease Indication
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country-Level Analysis & Forecast
17.8.1. India Vascular Endothelial Growth Factor Inhibitors Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug
17.8.1.2.2. By Types
17.8.1.2.3. By Disease Indication
17.8.1.2.4. By Distribution Channel
17.8.2. Indonesia Vascular Endothelial Growth Factor Inhibitors Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug
17.8.2.2.2. By Types
17.8.2.2.3. By Disease Indication
17.8.2.2.4. By Distribution Channel
17.8.3. Malaysia Vascular Endothelial Growth Factor Inhibitors Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug
17.8.3.2.2. By Types
17.8.3.2.3. By Disease Indication
17.8.3.2.4. By Distribution Channel
17.8.4. Thailand Vascular Endothelial Growth Factor Inhibitors Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Drug
17.8.4.2.2. By Types
17.8.4.2.3. By Disease Indication
17.8.4.2.4. By Distribution Channel
18. Oceania Vascular Endothelial Growth Factor Inhibitors Market 2012-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug
18.3.3. By Types
18.3.4. By Disease Indication
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug
18.4.3. By Types
18.4.4. By Disease Indication
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. Australia Vascular Endothelial Growth Factor Inhibitors Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug
18.8.1.2.2. By Types
18.8.1.2.3. By Disease Indication
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Vascular Endothelial Growth Factor Inhibitors Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug
18.8.2.2.2. By Types
18.8.2.2.3. By Disease Indication
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Vascular Endothelial Growth Factor Inhibitors Market Analysis 2012 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug
19.3.3. By Types
19.3.4. By Disease Indication
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug
19.4.3. By Types
19.4.4. By Disease Indication
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country-Level Analysis & Forecast
19.8.1. GCC Countries Vascular Endothelial Growth Factor Inhibitors Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug
19.8.1.2.2. By Types
19.8.1.2.3. By Disease Indication
19.8.1.2.4. By Distribution Channel
19.8.2. Turkey Vascular Endothelial Growth Factor Inhibitors Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug
19.8.2.2.2. By Types
19.8.2.2.3. By Disease Indication
19.8.2.2.4. By Distribution Channel
19.8.3. South Africa Vascular Endothelial Growth Factor Inhibitors Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug
19.8.3.2.2. By Types
19.8.3.2.3. By Disease Indication
19.8.3.2.4. By Distribution Channel
19.8.4. North Africa Vascular Endothelial Growth Factor Inhibitors Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug
19.8.4.2.2. By Types
19.8.4.2.3. By Disease Indication
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. Regional Footprint Analysis
20.3.2. Channel Footprint Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Pfizer Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financial
21.3.1.5. Key Developments
21.3.1.6. SWOT Analysis
21.3.1.7. Strategy Overview
21.3.1.7.1. Marketing Strategies
21.3.1.7.2. Channel Strategies
21.3.2. Novartis AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Key Financial
21.3.2.5. Key Developments
21.3.2.6. SWOT Analysis
21.3.2.7. Strategy Overview
21.3.2.7.1. Marketing Strategies
21.3.2.7.2. Channel Strategies
21.3.3. Sanofi SA
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Key Financial
21.3.3.5. Key Developments
21.3.3.6. SWOT Analysis
21.3.3.7. Strategy Overview
21.3.3.7.1. Marketing Strategies
21.3.3.7.2. Channel Strategies
21.3.4. Bayer Healthcare LLC
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Key Financial
21.3.4.5. Key Developments
21.3.4.6. SWOT Analysis
21.3.4.7. Strategy Overview
21.3.4.7.1. Marketing Strategies
21.3.4.7.2. Channel Strategies
21.3.5. F. Hoffmann-La Roche Ltd
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Key Financial
21.3.5.5. Key Developments
21.3.5.6. SWOT Analysis
21.3.5.7. Strategy Overview
21.3.5.7.1. Marketing Strategies
21.3.5.7.2. Channel Strategies
21.3.6. Amgen Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Key Financial
21.3.6.5. Key Developments
21.3.6.6. SWOT Analysis
21.3.6.7. Strategy Overview
21.3.6.7.1. Marketing Strategies
21.3.6.7.2. Channel Strategies
21.3.7. Eli Lilly and Company
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Key Financial
21.3.7.5. Key Developments
21.3.7.6. SWOT Analysis
21.3.7.7. Strategy Overview
21.3.7.7.1. Marketing Strategies
21.3.7.7.2. Channel Strategies
21.3.8. Eisai Co., Ltd.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Key Financial
21.3.8.5. Key Developments
21.3.8.6. SWOT Analysis
21.3.8.7. Strategy Overview
21.3.8.7.1. Marketing Strategies
21.3.8.7.2. Channel Strategies
21.3.9. Sino Pharma
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Key Financial
21.3.9.5. Key Developments
21.3.9.6. SWOT Analysis
21.3.9.7. Strategy Overview
21.3.9.7.1. Marketing Strategies
21.3.9.7.2. Channel Strategies
21.3.10. AMillioneal Pharmaceuticals Inc.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Sales Footprint
21.3.10.4. Key Financial
21.3.10.5. Key Developments
21.3.10.6. SWOT Analysis
21.3.10.7. Strategy Overview
21.3.10.7.1. Marketing Strategies
21.3.10.7.2. Channel Strategies
21.3.11. Exelixis, Inc.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Sales Footprint
21.3.11.4. Key Financial
21.3.11.5. Key Developments
21.3.11.6. SWOT Analysis
21.3.11.7. Strategy Overview
21.3.11.7.1. Marketing Strategies
21.3.11.7.2. Channel Strategies
21.3.12. HUTCHMED
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Sales Footprint
21.3.12.4. Key Financial
21.3.12.5. Key Developments
21.3.12.6. SWOT Analysis
21.3.12.7. Strategy Overview
21.3.12.7.1. Marketing Strategies
21.3.12.7.2. Channel Strategies
21.3.13. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Sales Footprint
21.3.13.4. Key Financial
21.3.13.5. Key Developments
21.3.13.6. SWOT Analysis
21.3.13.7. Strategy Overview
21.3.13.7.1. Marketing Strategies
21.3.13.7.2. Channel Strategies
21.3.14. Takeda Pharmaceutical Company Limited
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Sales Footprint
21.3.14.4. Key Financial
21.3.14.5. Key Developments
21.3.14.6. SWOT Analysis
21.3.14.7. Strategy Overview
21.3.14.7.1. Marketing Strategies
21.3.14.7.2. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
Table 01: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 02: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 03: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 04: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 05: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 06: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 07: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 08: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 09: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 10: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 11: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Region
Table 12: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Region
Table 13: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 14: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 15: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 16: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 17: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 18: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 19: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 20: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 21: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 22: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 23: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 24: North America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 24: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 26: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 27: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 28: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 29: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 30: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 31: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 32: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 33: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 34: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 35: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 36: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 37: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 38: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 39: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 40: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 41: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 42: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 43: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 44: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 45: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 46: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 47: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 48: Europe Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 49: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 50: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 51: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 52: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 53: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 54: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 55: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 56: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 57: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 58: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 59: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 60: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 61: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 62: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 63: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 64: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 65: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 66: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 67: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 68: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 69: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 70: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 71: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 72: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 73: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 74: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 75: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 76: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 77: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 78: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 79: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 80: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 81: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 82: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 83: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 84: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Table 85: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Country
Table 86: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Country
Table 87: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 88: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Drug
Table 89: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 90: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Drug
Table 91: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Types
Table 92: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Types
Table 93: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Disease Indication
Table 94: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Disease Indication
Table 95: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Analysis 2012 to 2021, By Distribution Channel
Table 96: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) Forecast 2022 to 2032, By Distribution Channel
Figure 01: Global Vascular Endothelial Growth Factor Inhibitors Market Value, 2012-2021
Figure 02: Global Vascular Endothelial Growth Factor Inhibitors Market Value (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 03: Global Vascular Endothelial Growth Factor Inhibitors Market Absolute $ Opportunity, 2022 to 2032
Figure 04: Global Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2022 to 2032
Figure 05: Global Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 06: Global Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2022 to 2032
Figure 07: Global Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 08: Global Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2022 to 2032
Figure 09: Global Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 10: Global Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 11: Global Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2022 to 2032
Figure 12: Global Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Region, 2022 to 2032
Figure 13: Global Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Region, 2022 to 2032
Figure 14: North America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 15: North America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 16: North America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 17: North America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 18: North America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 19: North America Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 20: North America Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 21: North America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 22: North America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 23: North America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 24: North America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 25: North America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 26: U.S. Market Value Proportion Analysis, 2021
Figure 27: U.S. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 28: U.S. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 29: U.S. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 30: U.S. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 31: Canada Market Value Proportion Analysis, 2021
Figure 32: Canada Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 33: Canada Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 34: Canada Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 35: Canada Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 36: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 37: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 38: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 39: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 40: Latin America Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 41: Latin America Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 42: Latin America Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 43: Latin America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 44: Latin America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 45: Latin America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 46: Latin America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 47: Latin America Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 48: Brazil Market Value Proportion Analysis, 2021
Figure 49: Brazil Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 50: Brazil Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 51: Brazil Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 52: Brazil Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 53: Mexico Market Value Proportion Analysis, 2021
Figure 54: Mexico Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 55: Mexico Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 56: Mexico Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 57: Mexico Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 58: Argentina Market Value Proportion Analysis, 2021
Figure 59: Argentina Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 60: Argentina Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 61: Argentina Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 62: Argentina Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 63: Europe Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 64: Europe Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 65: Europe Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 66: Europe Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 67: Europe Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 68: Europe Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 69: Europe Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 70: Europe Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 71: Europe Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 72: Europe Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 73: Europe Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 74: Europe Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 75: Germany Market Value Proportion Analysis, 2021
Figure 76: Germany Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 77: Germany Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 78: Germany Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 79: Germany Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 80: U.K. Market Value Proportion Analysis, 2021
Figure 81: U.K. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 82: U.K. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 83: U.K. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 84: U.K. Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 85: Italy Market Value Proportion Analysis, 2021
Figure 86: Italy Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 87: Italy Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 88: Italy Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 89: Italy Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 90: France Market Value Proportion Analysis, 2021
Figure 91: France Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 92: France Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 93: France Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 94: France Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 95: Spain Market Value Proportion Analysis, 2021
Figure 96: Spain Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 97: Spain Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 98: Spain Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 99: Spain Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 100: Russia Market Value Proportion Analysis, 2021
Figure 101: Russia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 102: Russia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 103: Russia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 104: Russia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 105: Nordic Countries Market Value Proportion Analysis, 2021
Figure 106: Nordic Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 107: Nordic Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 108: Nordic Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 109: Nordic Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 110: BENULUX Market Value Proportion Analysis, 2021
Figure 111: BENULUX Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 112: BENULUX Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 113: BENULUX Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 114: BENULUX Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 115: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 116: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 117: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 118: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 119: East Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 120: East Asia Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 121: East Asia Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 122: East Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 123: East Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 124: East Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 125: East Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 126: East Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 127: China Market Value Proportion Analysis, 2021
Figure 128: China Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 129: China Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 130: China Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 131: China Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 132: Japan Market Value Proportion Analysis, 2021
Figure 133: Japan Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 134: Japan Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 135: Japan Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 136: Japan Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 137: South Korea Market Value Proportion Analysis, 2021
Figure 138: South Korea Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 139: South Korea Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 140: South Korea Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 141: South Korea Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 142: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 143: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 144: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 145: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 146: South Asia Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 147: South Asia Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 148: South Asia Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 149: South Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 150: South Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 151: South Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 152: South Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 153: South Asia Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 154: India Market Value Proportion Analysis, 2021
Figure 155: India Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 156: India Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 157: India Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 158: India Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 159: Thailand Market Value Proportion Analysis, 2021
Figure 160: Thailand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 161: Thailand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 162: Thailand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 163: Thailand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 164: Indonesia Market Value Proportion Analysis, 2021
Figure 165: Indonesia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 166: Indonesia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 167: Indonesia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 168: Indonesia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 169: Malaysia Market Value Proportion Analysis, 2021
Figure 170: Malaysia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 171: Malaysia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 172: Malaysia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 173: Malaysia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 174: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 175: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 176: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 177: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 178: Oceania Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 179: Oceania Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 180: Oceania Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 181: Oceania Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 182: Oceania Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 183: Oceania Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 184: Oceania Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 185: Oceania Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 186: Australia Market Value Proportion Analysis, 2021
Figure 187: Australia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 188: Australia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 189: Australia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 190: Australia Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 191: New Zealand Market Value Proportion Analysis, 2021
Figure 192: New Zealand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 193: New Zealand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 194: New Zealand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 195: New Zealand Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 196: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Country (2022 E)
Figure 197: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Drug Type (2022 E)
Figure 198: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Types (2022 E)
Figure 199: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Disease Indication (2022 E)
Figure 200: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Value Share, By Distribution Channel (2022 E)
Figure 201: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) Analysis, 2012-2021
Figure 202: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Size (US$ Million) & Y-o-Y Growth (%), 2022 to 2032
Figure 203: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Drug, 2022 to 2032
Figure 204: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Types, 2022 to 2032
Figure 205: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Disease Indication, 2022 to 2032
Figure 206: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Distribution Channel, 2022 to 2032
Figure 207: Middle East & Africa Vascular Endothelial Growth Factor Inhibitors Market Attractiveness Analysis, By Country, 2022 to 2032
Figure 208: GCC Countries Market Value Proportion Analysis, 2021
Figure 209: GCC Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 210: GCC Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 211: GCC Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 212: GCC Countries Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 213: Turkey Market Value Proportion Analysis, 2021
Figure 214: Turkey Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 215: Turkey Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 216: Turkey Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 217: Turkey Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 218: North Africa Market Value Proportion Analysis, 2021
Figure 219: North Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 220: North Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 221: North Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 222: North Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Figure 223: South Africa Market Value Proportion Analysis, 2021
Figure 224: South Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Drug, 2021 to 2032
Figure 225: South Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Types, 2021 to 2032
Figure 226: South Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Disease Indication, 2021 to 2032
Figure 227: South Africa Vascular Endothelial Growth Factor Inhibitors Market Share Analysis (%) by Distribution Channel, 2021 to 2032
The global vascular endothelial growth factor inhibitors market is worth US$ 21.2 Billion in 2021 and is set to expand 1.5X over the next ten years.
The vascular endothelial growth factor inhibitors market is expected to reach US$ 33.5 Billion by the end of 2032, with sales revenue expected to register a 4.0% CAGR.
The growing burden of oncologic diseases, rising research on novel biologics, and greater awareness of the availability of therapeutics are some of the key trends in this market.
The US, China, Germany, Japan, and Australia, are expected to drive demand for the vascular endothelial growth factor inhibitors industry.
Demand for vascular endothelial growth factor inhibitors in South Asia is expected to register a 6.8% CAGR over the next ten years.
North America is one of the key markets for vascular endothelial growth factor inhibitors, with the US accounting for about 95.3% of the North American vascular endothelial growth factor inhibitors market in the year 2021.
Demand for vascular endothelial growth factor inhibitors in Europe is expected to register a 2.2% CAGR over the next ten years.
The US, China, and Germany are the key producers of vascular endothelial growth factor inhibitors.
Demand for vascular endothelial growth factor inhibitors in MEA is expected to register a 4.2% CAGR over the next ten years.
Pfizer Inc., Novartis AG, Sanofi SA, Bayer Healthcare LLC, F. Hoffmann-La Roche Ltd, Amgen Inc., Eli Lilly and Company, Eisai Co., Ltd., Sino Pharma, Amneal Pharmaceuticals Inc., Exelixis, Inc., HUTCHMED, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Company Limited, are some of the key players in the vascular endothelial growth factor inhibitors industry.
Explore Similar Insights
Vascular Endothelial Growth Factor Inhibitor Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
